Status:
RECRUITING
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Non Small Cell Lung Cancer NSCLC
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with advanced non-small cell lung cancer (NSCLC) usually undergo biopsies to obtain cytological material on which to perform Next Generation Sequencing (NGS) analysis, with the aim of identif...
Detailed Description
In patients with advanced non-small cell lung cancer (NSCLC), who often undergo biopsies, there is a growing need to clearly define the clinical role of liquid biopsies. Lung tumors can only be visual...
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- Indication for bronchoscopic cytological sampling for further diagnosis of suspected stage IV lung cancer on CT (computed tomography)/PET (positron emission tomography) scans, with consequent need for NGS analysis.
- Indication for bronchoscopy in patients with known lung cancer who have already undergone NGS analysis on a cytological-histological sample in the previous five years.
- Acquisition of written informed consent.
Exclusion
- Confirmation of small cell lung cancer or other non-NSCLC pathology where there is no indication for NGS testing.
Key Trial Info
Start Date :
January 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT07188480
Start Date
January 17 2025
End Date
October 31 2025
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138